Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Hall SAL, Burns GS, Anagnostou D, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden DS, Locarnini SA, Visvanathan K, Thompson AJ. Hall SAL, et al. Aliment Pharmacol Ther. 2022 Jul;56(2):310-320. doi: 10.1111/apt.16968. Epub 2022 May 6. Aliment Pharmacol Ther. 2022. PMID: 35521992
Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age.
Howell J, Anderson D, Bloom S, Lubel J, Kemp W, Williams J, Bell S, Croagh C, Demediuk B, Desmond P, Hall S, Holmes J, Hong T, Iser D, Lim L, Papaluca T, Ryan M, Visvanathan K, Xiao Y, van Gemert C, Hellard M, Thompson A. Howell J, et al. J Hepatol. 2020 Nov;73(5):1282-1284. doi: 10.1016/j.jhep.2020.06.031. Epub 2020 Sep 1. J Hepatol. 2020. PMID: 32888765 No abstract available.
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.
Hall SAL, Burns GS, Mooney BJ, Millen R, Morris R, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden S, Locarnini SA, Thompson AJ, Visvanathan K. Hall SAL, et al. J Infect Dis. 2022 Dec 28;227(1):123-132. doi: 10.1093/infdis/jiac375. J Infect Dis. 2022. PMID: 36108079
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.
Thompson AJ, Jackson K, Bonanzinga S, Hall SAL, Hume S, Burns GS, Sundararajan V, Ratnam D, Levy MT, Lubel J, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Sinclair M, Meredith C, Matthews G, Revill PA, Littlejohn M, Bowden DS, Canchola JA, Torres J, Siew P, Lau J, La Brot B, Kuchta A, Visvanathan K. Thompson AJ, et al. Among authors: hall sal. Hepatol Commun. 2023 Jul 17;7(8):e0188. doi: 10.1097/HC9.0000000000000188. eCollection 2023 Aug 1. Hepatol Commun. 2023. PMID: 37459199 Free PMC article. Clinical Trial.
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.
Hume SJ, Wong DK, Yuen MF, Jackson K, Bonanzinga S, Vogrin S, Hall SAL, Burns GS, Desmond PV, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Ngu MC, Sinclair M, Meredith C, Matthews G, Revill PA, Littlejohn M, Bowden S, Visvanathan K, Holmes JA, Thompson AJ. Hume SJ, et al. Among authors: hall sal. Liver Int. 2024 Oct;44(10):2605-2614. doi: 10.1111/liv.16029. Epub 2024 Jul 15. Liver Int. 2024. PMID: 39007640